Nerve repair device house Orthocell is taking a cautious approach to entering the US market, with a staged approach to ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

Good morning! Here’s everything you need to know before the ASX flings open its doors and begins trading today.

EchoIQ’s heart-failure AI just hit Mayo’s testing track, chasing FDA clearance and a shot at fixing America’s $60bn hospital headache.

South African gold output has steadily declined for three decades. Record prices and political stability are bringing the ...

The ASX fell sharply in afternoon trade but then found its way to a level footing following the RBA's cash rate hold.

Dental supplier SDI's full-year revenue has been crimped by an ongoing migration from amalgam fillings that contain mercury.

The ASX has crawled to a flattish position at lunch, supported by strength in tech and gold stocks as fresh tariff turmoil ...

GCM VHD Technology graphite heat sink outperforms traditional methods in Finite Element modelling with power load capacity almost double.

Investors have rushed into passive ETFs, which perfectly match market moves. But are the funds themselves changing the ...

Western Yilgarn (ASX:WYX) has announced a 16.5-million-tonne bauxite resource estimate for its Cardea-3 deposit in Western Australia.

Tylah Tully is joined in this episode of What the Facts by Prescient Therapeutics (ASX:PTX) CEO James McDonnell.